Basis of Presentation and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2011

Basis of Presentation and Summary of Significant Accounting Policies

Schedule of assets measured at fair value on a recurring basis

	Fair Value Measurements at September 30, 2011 Using:
			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	62,709	$	62,709	$	—	$	—
Corporate debt securities	92,757		—		92,757		—
U.S. treasury and government agency securities	44,310		—		44,310		—
Commercial paper	12,993		—		12,993		—
Auction rate securities	25,131		—		—		25,131
	$	237,900	$	62,709	$	150,060	$	25,131

	Fair Value Measurements at December 31, 2010 Using:
			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
Money market funds	$	110,238	$	110,238	$	—	$	—
Corporate debt securities	83,768		—		83,768		—
U.S. treasury and government agency securities	50,925		—		50,925		—
Foreign government securities	2,431		—		2,431		—
Commercial paper	10,495		—		10,495		—
Auction rate securities	33,597		—		—		33,597
	$	291,454	$	110,238	$	147,619	$	33,597

Rollforward of assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3)

	Nine Months Ended
	September 30, 2011
Balance at beginning of period	$	33,597
Transfers to Level 3	—
Total gains (losses) (realized or unrealized):
Included in earnings	(210		)
Included in other comprehensive income (loss)	2,694
Purchases, issuances, sales, and settlements:	—
Purchases	—
Issuances	—
Sales	—
Settlements	(10,950		)
Balance at end of period	$	25,131
The amount of total gains (losses) for the period included in earnings attributable to the change in unrealized gains (losses) relating to assets still held at end of period	$	—

Analysis of product sales allowances and accruals

	Three Months Ended September 30,
	2011			2010
Product sales allowances and accruals
Discounts and chargebacks	$	3,601		$	1,218
Government and other rebates	2,120			4,383
Medicaid rebate reserve adjustment	(3,026		)	—
Returns	354			359
Total product sales allowances and accruals	$	3,049		$	5,960
Total gross product sales	$	18,851		$	21,133
Total product sales allowances and accruals as a percent of total gross product sales	16		%	28		%

	Nine Months Ended September 30,
	2011			2010
Product sales allowances and accruals
Discounts and chargebacks	$	9,400		$	3,035
Government and other rebates	6,897			11,917
Medicaid rebate reserve adjustment	(2,532		)	—
Returns	1,022			936
Total product sales allowances and accruals	$	14,787		$	15,888
Total gross product sales	$	54,692		$	60,582
Total product sales allowances and accruals as a percent of total gross product sales	27		%	26		%

Schedule of customers representing 10% or more of revenues

	Nine Months Ended September 30,
	2011		2010
AmerisourceBergen Drug Corporation	42	%	36	%
McKesson Corporation	20	%	<10	%
Takeda Pharmaceutical Company Limited	13	%	<10	%
Cardinal Health, Inc.	12	%	<10	%
Metro Medical Supply, Inc.	<10	%	21	%